Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMUEL A KANTOR

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1316909864
CMS profile
332063
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$52,522.73

243 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMUEL A KANTOR

NPI 1316909864 · CMS profile ID 332063

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316909864?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMUEL A KANTOR, NPI 1316909864, CMS profile ID 332063. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316909864?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SAMUEL A KANTOR, NPI 1316909864, CMS profile ID 332063. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316909864?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SAMUEL A KANTOR, NPI 1316909864, CMS profile ID 332063, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1316909864?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

243 matching records · $52,522.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 243 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 243.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vifor Pharma, Inc. $121.8410/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816135287 CMS
AstraZeneca Pharmaceuticals LP $232.9610/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829632905 CMS
AstraZeneca Pharmaceuticals LP $100.6910/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829735351 CMS
AstraZeneca Pharmaceuticals LP $54.3910/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829772793 CMS
AstraZeneca Pharmaceuticals LP $181.6710/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830008697 CMS
Aurinia Pharma U.S., Inc. $121.9510/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841402331 CMS
Bayer HealthCare Pharmaceuticals Inc. $5.8810/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789122299 CMS
GlaxoSmithKline, LLC. $13.4610/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803151201 CMS
AstraZeneca Pharmaceuticals LP $18.3810/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829833659 CMS
Horizon Therapeutics plc $17.5710/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797155509 CMS
Fresenius USA Marketing, Inc. $5.2610/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849403861 CMS
Fresenius USA Marketing, Inc. $120.5510/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849403881 CMS
Vifor Pharma, Inc. $8.2510/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816133567 CMS
Bayer HealthCare Pharmaceuticals Inc. $2,406.0010/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789166145 CMS
Horizon Therapeutics plc $8.7710/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797155507 CMS
Ultragenyx Pharmaceutical Inc. $24.8810/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848963685 CMS
AstraZeneca Pharmaceuticals LP $1,000.0010/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830141225 CMS
Bayer HealthCare Pharmaceuticals Inc. $103.6410/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789081869 CMS
AstraZeneca Pharmaceuticals LP $1,000.0009/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829703271 CMS
AstraZeneca Pharmaceuticals LP $650.0009/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829845699 CMS
AstraZeneca Pharmaceuticals LP $650.0009/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830149817 CMS
Vifor Pharma, Inc. $17.7909/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816131589 CMS
AstraZeneca Pharmaceuticals LP $19.0009/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829820665 CMS
AstraZeneca Pharmaceuticals LP $15.4209/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829865033 CMS
GlaxoSmithKline, LLC. $4.8709/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802783032 CMS
Daiichi Sankyo Inc. $15.1509/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836321153 CMS
Horizon Therapeutics plc $16.5909/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797155505 CMS
Bayer HealthCare Pharmaceuticals Inc. $1.2309/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789062711 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.0609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789104141 CMS
Fresenius USA Marketing, Inc. $4.8309/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849403845 CMS
Horizon Therapeutics plc $109.5409/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797155503 CMS
AstraZeneca Pharmaceuticals LP $22.9209/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829928355 CMS
Bayer HealthCare Pharmaceuticals Inc. $123.8909/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789092901 CMS
Fresenius USA Marketing, Inc. $1.0009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849403809 CMS
Fresenius USA Marketing, Inc. $3.5909/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849403821 CMS
Ultragenyx Pharmaceutical Inc. $22.7009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848963683 CMS
Vifor Pharma, Inc. $21.3809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816127501 CMS
Bayer HealthCare Pharmaceuticals Inc. $8.3809/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789116461 CMS
Bayer HealthCare Pharmaceuticals Inc. $2,005.0009/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789157365 CMS
AstraZeneca Pharmaceuticals LP $21.1009/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830189347 CMS
OPKO Pharmaceuticals, LLC $17.2409/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827745009 CMS
Fresenius USA Marketing, Inc. $4.9308/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849403853 CMS
GlaxoSmithKline, LLC. $14.7908/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802471161 CMS
Otsuka America Pharmaceutical, Inc. $1.5508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834742147 CMS
Otsuka America Pharmaceutical, Inc. $9.5208/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834742145 CMS
Vifor Pharma, Inc. $1,500.0008/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816124659 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,690.0008/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789150551 CMS
Horizon Therapeutics plc $2,340.0008/19/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797155501 CMS
AstraZeneca Pharmaceuticals LP $20.8708/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830148571 CMS
Daiichi Sankyo Inc. $19.5008/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836313639 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,712.56 244
PY2020 $7,958.89 135
PY2021 $52,522.73 243
PY2022 $81,147.05 304
PY2023 $68,933.37 244
PY2024 $40,231.23 247
PY2025 $41,989.01 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $47,819.04 14
PY2022 Principal investigator $213,274.87 80
PY2021 Principal investigator $134,550.26 37
PY2020 Principal investigator $141,788.75 29
PY2019 Principal investigator $158,224.22 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,520.20 12/31/2023 Non-covered Recipient Entity
NEVADA KIDNEY DISEASE AND HYPERTENSION CENTERS
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia No dispute reported 06/30/2026 991124695
Principal investigator 1 AKEBIA THERAPEUTICS INC $300.00 07/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919933
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,600.00 06/20/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919983
Principal investigator 1 AKEBIA THERAPEUTICS INC $300.00 06/20/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999920005
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,225.00 03/01/2023 Non-covered Recipient Entity
FRESENIUS MEDICAL CARE NORTH AMERICA
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1017235017
Principal investigator 1 AKEBIA THERAPEUTICS INC $157.00 02/27/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919899
Principal investigator 1 AKEBIA THERAPEUTICS INC $117.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919811
Principal investigator 1 AKEBIA THERAPEUTICS INC $157.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919833
Principal investigator 1 AKEBIA THERAPEUTICS INC $203.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919853
Principal investigator 1 AKEBIA THERAPEUTICS INC $349.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919877
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,200.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,982.56 01/19/2023 Non-covered Recipient Entity
NEVADA KIDNEY DISEASE AND HYPERTENSION CENTERS
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia No dispute reported 06/30/2026 991128007
Principal investigator 1 Novartis Pharmaceuticals Corporation $248.28 01/10/2023 Non-covered Recipient Entity
FRENOVA SMO
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1017187777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,460.00 01/01/2023 Non-covered Recipient Entity
Nevada Kidney Disease And Hypertension Center-Fire Mesa
BI 685509 Dose finding PoCC in Non Diabetic CKD No dispute reported 06/30/2026 1022142485